4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
4D Molecular Therapeutics, Inc. (FDMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 1.63 million shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2023-11-09
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2023-09-30 was 0.00 shares.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2023-06-30 was 0.00 shares.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2023-03-31 was 1.63M shares, a 1.25% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2022-12-31 was 0.00 shares.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2022 was 1.61M shares, a 20.77% increase from fiscal 2021.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2021 was 1.33M shares, a 61.53% decline from fiscal 2020.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2020 was 3.47M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 12 month |
|---|---|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-09 | 1.63M shares 10-Q · filed 2023-11-09 | 1.63M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 1.63M shares 10-Q · filed 2023-08-09 | 1.63M shares derived: sum of 3 quarters · filed 2023-08-09 | 1.63M shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 1.63M shares 10-Q · filed 2023-05-11 | 1.63M shares derived: sum of 2 quarters · filed 2023-05-11 | 1.63M shares derived: sum of 3 quarters · filed 2023-05-11 | 1.63M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-15 | 0.00 shares derived: sum of 3 quarters · filed 2023-03-15 | 1.61M shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-08 | 1.61M shares 10-Q · filed 2022-11-08 | 1.61M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.61M shares 10-Q · filed 2022-08-11 | 1.61M shares derived: sum of 3 quarters · filed 2022-08-11 | 1.61M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 1.61M shares 10-Q · filed 2022-05-12 | 1.61M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.61M shares derived: sum of 3 quarters · filed 2022-05-12 | 1.61M shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 0.00 shares derived: sum of 2 quarters · filed 2022-03-28 | 0.00 shares derived: sum of 3 quarters · filed 2022-03-28 | 1.33M shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-10 | 1.33M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 1.33M shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 1.33M shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 3.47M shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |